<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genetic tests for individualized <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy are now expanding their repertoire as pharmacogenomics biomarkers, coupled with advances in molecular targeted therapy </plain></SENT>
<SENT sid="1" pm="."><plain>These tests were considered special in the 1990s, because they were almost entirely limited to <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumors</z:e> and other rare <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Molecular targeted therapy has been applied to common <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> as well as <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumors</z:e> in the first decade of the 21st century, leading to a breakthrough in genetic tests </plain></SENT>
<SENT sid="3" pm="."><plain>In this symposium, recent advances in genetic tests for molecular targeted therapy are being presented on <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumors</z:e> by 4 speakers </plain></SENT>
</text></document>